Knowledge Library
Validation of GVHD in mouse model for preclinical efficacy screen
AACR Annual meeting 2021 Na Xu, Ya Zhang, Rou Xie, Lijun Jia, Yingying Cai, Qing Lin Oncology and Immunology Unit,...
Continue Reading
Faster with high-speed fragment screening — Accelerate your drug discovery campaign
In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited...
Continue Reading
Enabling Technology for Targeted Protein Degradation
Summary Traditional small molecule therapeutic mechanisms have recently been augmented by a new strategy to specifically manipulate the levels of...
Continue Reading
Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C...
Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation...
Continue Reading Targeted Protein Degradation Platform
Integrated Services BIOLOGY & PHARMACOLOGY BINARY/TERNARY COMPLEX FORMATION Biochemical & Biophysical Assays Biochemical binding assay Cellular Assays TARGET UBIQUITINATION &...
Continue Reading Virology and Viral Vector Platforms
WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy...
Continue Reading WuXi AppTec in vitro Safety Pharmacology Profiling
Comprehensive in vitro off-target screening services Safety-related drug failure is a major challenge for the pharmaceutical industry. Approximately 75% of...
Continue Reading In Vitro Toxicity Services
Identify Potential Liability Issues in the Early Stages of Drug Discovery Drug-induced toxicity is a primary cause of failure for...
Continue Reading